INmune Bio (INMB) Competitors $1.98 -0.03 (-1.49%) Closing price 04:00 PM EasternExtended Trading$2.02 +0.04 (+2.02%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMB vs. ENTA, CRBU, TNXP, EPRX, NLTX, PLX, GNFT, ACRS, BIOA, and SLSShould you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Enanta Pharmaceuticals (ENTA), Caribou Biosciences (CRBU), Tonix Pharmaceuticals (TNXP), Eupraxia Pharmaceuticals (EPRX), Neoleukin Therapeutics (NLTX), Protalix BioTherapeutics (PLX), GENFIT (GNFT), Aclaris Therapeutics (ACRS), BioAge Labs (BIOA), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry. INmune Bio vs. Its Competitors Enanta Pharmaceuticals Caribou Biosciences Tonix Pharmaceuticals Eupraxia Pharmaceuticals Neoleukin Therapeutics Protalix BioTherapeutics GENFIT Aclaris Therapeutics BioAge Labs SELLAS Life Sciences Group Enanta Pharmaceuticals (NASDAQ:ENTA) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Does the media prefer ENTA or INMB? In the previous week, Enanta Pharmaceuticals had 2 more articles in the media than INmune Bio. MarketBeat recorded 6 mentions for Enanta Pharmaceuticals and 4 mentions for INmune Bio. Enanta Pharmaceuticals' average media sentiment score of 0.80 beat INmune Bio's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, ENTA or INMB? Enanta Pharmaceuticals has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Which has higher earnings and valuation, ENTA or INMB? INmune Bio has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnanta Pharmaceuticals$67.64M3.62-$116.04M-$4.32-2.65INmune Bio$10K5,262.84-$42.08M-$2.48-0.80 Is ENTA or INMB more profitable? INmune Bio has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -141.98%. Enanta Pharmaceuticals' return on equity of -89.02% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets Enanta Pharmaceuticals-141.98% -89.02% -27.28% INmune Bio N/A -120.62%-92.94% Do institutionals and insiders have more ownership in ENTA or INMB? 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 13.9% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 35.7% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend ENTA or INMB? Enanta Pharmaceuticals presently has a consensus price target of $20.83, suggesting a potential upside of 81.79%. INmune Bio has a consensus price target of $18.50, suggesting a potential upside of 834.34%. Given INmune Bio's higher probable upside, analysts clearly believe INmune Bio is more favorable than Enanta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71INmune Bio 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.38 SummaryINmune Bio beats Enanta Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMB vs. The Competition Export to ExcelMetricINmune BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.63M$12.26B$9.05B$10.60BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-0.8021.4785.8427.34Price / Sales5,262.84275.54535.76202.47Price / CashN/A47.1237.9261.55Price / Book1.3710.4313.056.78Net Income-$42.08M-$52.40M$3.30B$275.79M7 Day Performance-7.48%6.37%4.81%2.64%1 Month Performance11.24%16.15%9.99%9.14%1 Year Performance-61.48%33.90%85.26%35.89% INmune Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMBINmune Bio2.3584 of 5 stars$1.98-1.5%$18.50+834.3%-62.1%$52.63M$10K-0.8010News CoveragePositive NewsAnalyst ForecastGap UpENTAEnanta Pharmaceuticals4.0416 of 5 stars$11.35+9.9%$20.83+83.6%+2.7%$220.83M$67.64M-2.63160Analyst ForecastCRBUCaribou Biosciences1.8469 of 5 stars$2.34+3.1%$6.67+184.9%+41.8%$211.39M$9.99M-1.31100News CoverageAnalyst ForecastTNXPTonix Pharmaceuticals2.8081 of 5 stars$24.22+0.9%$70.00+189.0%+60.0%$210.38M$10.09M-0.6150Analyst ForecastEPRXEupraxia Pharmaceuticals2.8489 of 5 stars$5.97+2.1%$11.00+84.3%+167.0%$210.37MN/A-7.0229Analyst ForecastAnalyst RevisionNLTXNeoleukin TherapeuticsN/A$22.34+6.5%N/A-53.4%$209.95MN/A-7.1890High Trading VolumePLXProtalix BioTherapeutics1.9754 of 5 stars$2.60+7.0%$15.00+476.9%+154.5%$207.30M$61.95M-20.00200GNFTGENFIT1.1339 of 5 stars$4.08-0.1%$7.00+71.8%-30.0%$203.93M$76.77M0.00120Gap UpACRSAclaris Therapeutics2.0251 of 5 stars$1.90+2.2%$8.71+358.6%+63.8%$201.50M$16.79M-1.39100Positive NewsBIOABioAge Labs0.18 of 5 stars$5.63+0.4%N/AN/A$201.12MN/A0.00N/ANews CoverageAnalyst ForecastSLSSELLAS Life Sciences Group2.2578 of 5 stars$1.89+1.1%$7.00+270.4%+58.2%$196.91M$1M-5.9110News CoveragePositive NewsAnalyst ForecastShort Interest ↓ Related Companies and Tools Related Companies Enanta Pharmaceuticals Competitors Caribou Biosciences Competitors Tonix Pharmaceuticals Competitors Eupraxia Pharmaceuticals Competitors Neoleukin Therapeutics Competitors Protalix BioTherapeutics Competitors GENFIT Competitors Aclaris Therapeutics Competitors BioAge Labs Competitors SELLAS Life Sciences Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INMB) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
